Meitav's Strategic Investments
Meitav Investment House significantly increases stakes in ETOR, SPYM, and SPGI; trims small cap.
Anonymous
Key Points
1
Goldman Sachs raised its price target on eToro Group Ltd. (ETOR) from $39 to $43 and assigned a neutral rating, signaling a more favorable near-term view despite the stock's volatility.
2
Montz Harcus Wealth Management LLC reports SPDR S&P 500 ETF (SPYM) as its largest holding, with 449,889 shares, making up about 13.9% of its portfolio.
3
Meitav’s stake in SPDR MSCI ACWI ex-US ETF (CWI) stood at 52,526 shares after adding 24,833 during the quarter, representing roughly 0.08% of the ETF and valued at about $1.92 million at quarter end.
4
In SPDR Portfolio S&P 600 Small Cap ETF (SPSM), Concurrent Investment Advisors LLC increased its SPSM stake to 44,616 shares in the fourth quarter, a substantial rise that backed its position at about $2.09 million.
5
SPGI activity shows broad institutional interest: Norges Bank opened a new SPGI position in the fourth quarter, while Cardano Risk Management B.V. and T. Rowe Price each expanded SPGI holdings by large multiples during the period (858.3% and 2,256.7%, respectively), highlighting widespread investor demand for S&P Global shares.
Meitav Investment House Ltd. added 12,900 shares of eToro Group Ltd. (ETOR) in the first quarter, spending roughly $387,000 to expand its position in the newly public trading platform, according to Watchlist News.
The Israeli investment house was busy across many positions during the quarter — boosting some bets by hundreds of percent while trimming others. The moves show a firm actively reshaping its portfolio as markets shifted in early 2025.
eToro Buy Comes With Goldman's Upgraded Price Target
Meitav's $387,000 eToro purchase gives it a stake in the online brokerage that went public recently under the ticker ETOR. Goldman Sachs raised its price target on ETOR from $39 to $43 during the same period, assigning a neutral rating, according to Watchlist News. That signals a cautiously more favorable view of the stock despite ongoing volatility.
eToro has drawn attention from institutional investors since its listing. Meitav's entry at roughly $30 per share — implied by the $387,000 outlay for 12,900 shares — suggests the firm moved in before the Goldman target revision was widely priced in.
S&P Global Stake Surges 643% in a Single Quarter
The boldest move Meitav made was in S&P Global Inc. (SPGI). The firm bought 31,358 additional shares, lifting its total to 36,233 shares worth about $15.37 million, per Watchlist News. That is a 643.2% jump in one quarter — a dramatic bet on the financial data giant.
Meitav was not alone. Norges Bank opened a brand-new SPGI position in the fourth quarter. Cardano Risk Management B.V. grew its stake by 858.3%. T. Rowe Price expanded its SPGI holdings by a striking 2,256.7%, according to Watchlist News. Big money is clearly moving into S&P Global shares.
ETF Reshuffling: Meitav Piles Into Global Stocks, Cuts Small Caps
Meitav nearly doubled its position in the SPDR MSCI ACWI ex-US ETF (CWI), adding 24,833 shares for a total of 52,526 shares worth $1.92 million — an 89.7% increase, reported Watchlist News. CWI tracks large international stocks outside the United States, so this move signals more confidence in global markets.
At the same time, Meitav cut its position in the SPDR Portfolio S&P 600 Small Cap ETF (SPSM) by 21.8%, bringing it down to 95,194 shares valued at about $4.6 million. Small-cap stocks have been under pressure in 2025, and Meitav appears to be reducing that risk while adding to broader global exposure.
S&P 500 ETF Position Reaches $34 Million in Value
Meitav also raised its stake in the SPDR Portfolio S&P 500 ETF (SPYM) to 449,889 shares, now worth around $34.435 million, according to Watchlist News. That makes SPYM one of the firm's largest single holdings. Montz Harcus Wealth Management LLC holds the same number of SPYM shares — 449,889 — making it that firm's top holding at 13.9% of its portfolio.
Elsewhere, Meitav trimmed its SPDR S&P Biotech ETF (XBI) position by 16.5%, selling 159,840 shares but still holding 809,579 shares. It also nudged up its stake in the Global X U.S. Infrastructure Development ETF (PAVE) by 1.3% to 1,221,025 shares, per Watchlist News. Taken together, the moves show a firm leaning toward large-cap and global exposure while pulling back from biotech and small caps.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
31
Articles
12
Reach
43
A
AnonymousAuthor
